Engineering Probiotics for the Management of Antibiotic Impacts on the Gut Microbiome
Time: 11:30 am
day: Conference Day Two, Track Two, AM
Details:
- Critical unmet need in healthcare: exploring how common antibiotic treatments can disrupt beneficial gut bacteria, leading to potential health issues
- Introduction to FLR-101, an engineered yeast strain designed to produce enzymes that locally degrade specific antibiotics in the gut, thereby managing impacts to the microbiome without compromising the efficacy of the treatment
- Regulatory Strategy and Medical Food Classification: Discussing Florey's unique approach to navigating regulatory pathways by developing FLR-101 as a medical food, aiming for efficient market entry and broad accessibility
- Future Directions in Engineered Probiotics: Outlining plans for expanding the application of Florey's synthetic biology platform to develop additional probiotics targeting various health conditions influenced by the gut microbiome
